3,5-双(甲基磺酰基)苯胺 | 51859-12-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-双(甲基磺酰基)苯胺
• 英文名称: 3,5-bis(methylsulfonyl)aniline
• 英文别名: 3,5-bis-methanesulfonyl-aniline；3,5-Bis-methansulfonyl-anilin；3.5-Di(methylsulfonyl)anilin
• CAS: 51859-12-2
• 化学式: C₈H₁₁NO₄S₂
• mdl: MFCD01464121
• 分子量: 249.312
• InChiKey: DLJOVNXLPVHDMZ-UHFFFAOYSA-N

物化性质

• 熔点：
  202～205℃

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2921420090

反应信息

• 作为反应物：
  描述：

  2-氨基-4-氯-6-甲基嘧啶 、 3,5-双(甲基磺酰基)苯胺 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 1.5h， 以59%的产率得到N⁴-(3,5-bis(methylsulfonyl)phenyl)-6-methylpyrimidine-2,4-diamine
  参考文献：
  名称：

  Species-Selective Pyrimidineamine Inhibitors of Trypanosoma brucei S-Adenosylmethionine Decarboxylase

  摘要：

  New therapeutic options are needed for treatment of human African trypanosomiasis (HAT) caused by protozoan parasite Trypanosoma brucei. S-Adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme in the polyamine pathway of T. brucei. Previous attempts to target this enzyme were thwarted by the lack of brain penetration of the most advanced series. Herein, we describe a T. brucei AdoMetDC inhibitor series based on a pyrimidineamine pharmacophore that we identified by target-based high-throughput screening. The pyrimidineamines showed selectivity for T. brucei AdoMetDC over the human enzyme, inhibited parasite growth in whole-cell assay, and had good predicted blood-brain barrier penetration. The medicinal chemistry program elucidated structure-activity relationships within the series. Features of the series that were required for binding were revealed by determining the X-ray crystal structure of TbAdoMetDC bound to one analog. The pyrimidineamine series provides a novel starting point for an anti-HAT lead optimization.

  DOI：

  10.1021/acs.jmedchem.7b01654
• 作为产物：
  描述：

  1,3-bis-methanesulfonyl-5-nitro-benzene 在 乙醇 、 镍 作用下， 生成 3,5-双(甲基磺酰基)苯胺
  参考文献：
  名称：

  Bolssens et al., Recueil des Travaux Chimiques des Pays-Bas, 1954, vol. 73, p. 819,829

  摘要：

  DOI：

文献信息

• N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cai Xiong Sui

  公开号：US20070099877A1

  公开（公告）日：2007-05-03

  Disclosed are N-aryl-thienopyrimidin-4-amines and analogs thereof, represented by the Formulae I-II: wherein Ar and R 1 -R 4 are defined herein. The present invention relates to the discovery that compounds having Formulae I-II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  揭示了N-芳基噻吩吡嘧啶-4-胺及其类似物，由以下的式子I-II表示：其中Ar和R1-R4在此有所定义。本发明涉及发现具有式子I-II的化合物是半胱氨酸蛋白酶的激活剂和凋亡诱导剂。因此，本发明的半胱氨酸蛋白酶激活剂和凋亡诱导剂可用于诱导在各种临床病况中发生细胞死亡，这些病况中存在细胞不受控制的生长和异常细胞的扩散。
• Glucagon antagonists/inverse agonists
  申请人：——

  公开号：US20030220350A1

  公开（公告）日：2003-11-27

  A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.

  一种新型化合物，可以拮抗胰高血糖素对胰高血糖素受体的作用。由于它们对胰高血糖素受体的拮抗作用，这些化合物可能适用于治疗和/或预防任何胰高血糖素介导的疾病和病症，如高血糖、1型糖尿病、2型糖尿病和肥胖症。
• Glucagon Antagonists/Inverse Agonists
  申请人：Lau Jesper

  公开号：US20090143592A1

  公开（公告）日：2009-06-04

  A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.

  一种新型化合物，可拮抗胰高血糖素对胰高血糖素受体的作用。由于这些化合物对胰高血糖素受体的拮抗作用，这些化合物可能适用于治疗和/或预防任何胰高血糖素介导的疾病和病症，如高血糖、1型糖尿病、2型糖尿病和肥胖症。
• GLUCAGON ANTAGONISTS/INVERSE AGONISTS
  申请人：NOVO NORDISK A/S

  公开号：EP1183229B1

  公开（公告）日：2005-10-26
• SAR study of 1,2-benzisothiazole dioxide compounds that agonize HIF-2 stabilization and EPO production
  作者：Wanbin Song、Jingjing Zhuang、Nan Zhang、Xintong Ren、Weiwei Xu、Mengqi Guo、Xiaotong Diao、Chao Liu、Jiaming Jin、Dalei Wu、Yinan Zhang

  DOI：10.1016/j.bmc.2022.117041

  日期：2023.1